Clinical trial
Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
NCT00408018 · Piramal Enterprises Limited, Industry · Terminated
Key facts
| NCT number | NCT00408018 |
|---|---|
| Title | Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
| Official title | An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms |
| Lead sponsor | Piramal Enterprises Limited, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasm |
| Intervention type | Drug |
| Interventions | P276-00 |
| Enrollment | 28 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Dec 5, 2006 |
| Last update posted | Jan 1, 2009 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: